FDA approves new antiplatelet drug used during heart procedure – The U.S. Food and Drug Administration approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart.
Researchers take the inside route to halt bleeding — Synthetic platelets halve clotting time – Blood loss is a major cause of death from roadside bombs to freeway crashes. Traumatic injury, the leading cause of death for people age 4 to 44, often overwhelms the body’s natural blood-clotting process.
FDA approved Amgen’s Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder ITP that can lead to serious bleeding. – The U.S. Food and Drug Administration approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.
The U.S. Food and Drug Administration approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and
Mechanism Behind Blood Stem Cells’ Longevity Discovered – The blood stem cells that live in bone marrow are at the top of a complex family tree. Such stem cells split and divide down various pathways that ultimately produce red cells, white cells and platelets. These “daughter” cells must be produced at a rate of about one million per second to constantly replenish the body’s blood supply.
Texting heart medication reminders improved patient adherence – Getting reminder texts helped patients take their heart medicines (anti-platelet and cholesterol-lowering drugs) more regularly, according to research presented at the American Heart Association’s Scientific Sessions 2013.
Diabetic stroke risk after AMI drops in 10 year period – At the ESC Congress researchers reveal that reperfusion therapy and secondary prevention drugs produced the decline and brought stroke risk after AMI closer to that of non-diabetics.
US FDA approves new treatment for late-stage breast cancer – Kadcyla (ado-trastuzumab emtansine) – a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer is approved by US FDA. Breast cancer is the second leading cause of cancer-related death among women. Almost 20 percent of breast cancers have increased amounts of the HER2 protein.
Elderly at risk of hospitalizations from key medications — Promoting safe use of blood thinners and diabetes medications can protect patients – Handful of drugs are responsible for most emergency room visits by patients in US, revealed by CDC researchers (US Centers for Disease Control and Prevention) in a recent study.
Heparin sodium allergy may lead to heparin-induced thrombocytopenia – A serious side-effect of heparin is heparin-induced thrombocytopenia (HIT). HIT is caused by an immunological reaction that makes platelets a target of immunological response, resulting in the degradation of platelets.
